secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001104659-25-019462
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix reports FY2024 revenue $63.7M, net loss $(193.5)M; updates AXPAXLI registrational program
--------------------------------------------------------------------------------

- Q4 2024 revenue $17.1M (+15.4% YoY); FY2024 revenue $63.7M (+9.0% YoY). Net loss $(193.5)M for FY2024 vs $(80.7)M in FY2023.
- Cash balance $392.1M as of Dec 31, 2024; expected to fund operations into 2028; no plans to raise additional capital in 2025.
- SOL-1 Phase 3 wet AMD trial amended to include re-dosing at Weeks 52 and 76; Week 36 primary endpoint data expected in 1Q 2026.
- SOL-R trial size reduced from 825 to 555 subjects due to re-dosing inclusion in SOL-1; non-inferiority margin -4.5 letters BCVA vs aflibercept.
- FDA feedback on AXPAXLI clinical trial design for NPDR and DME anticipated in 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/0001104659-25-019462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/tm258051d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-019462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer